Crinetics Pharmaceuticals (CRNX) Stock Chart & Stock Price History $33.39 +0.08 (+0.24%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Crinetics Pharmaceuticals Stock Price Performance 5 Day Performance+3.09%1 Month Performance+9.05%3 Month Performance-17.15%6 Month Performance-41.10%Year-To-Date Performance-34.70%1 Year Performance-25.88% Receive CRNX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRNX Stock Chart for Thursday, May, 1, 2025 CRNX Chart by TradingView Crinetics Pharmaceuticals Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization04/30/2025$33.31$33.39+0.24%$33.80$32.84662,955 shs$3.13 billion04/29/2025$33.11$33.31+0.60%$33.59$32.21737,016 shs$3.12 billion04/28/2025$32.39$33.11+2.22%$33.60$32.43605,996 shs$3.08 billion04/25/2025$33.39$32.39-2.99%$33.02$31.68835,521 shs$3.01 billion04/24/2025$32.37$33.39+3.15%$33.46$31.74981,487 shs$3.11 billion04/23/2025$31.27$32.37+3.52%$32.89$31.821.55 million shs$3.01 billion04/22/2025$30.15$31.27+3.71%$31.30$30.45603,241 shs$2.91 billion04/21/2025$30.42$30.15-0.89%$31.43$29.97669,840 shs$2.81 billion04/18/2025$30.42$30.42$30.58$29.42591,222 shs$2.83 billion04/17/2025$29.58$30.42+2.84%$30.58$29.42591,222 shs$2.83 billion Get the Latest News and Ratings for CRNX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 04/16/2025$29.66$29.58-0.27%$29.78$28.75706,748 shs$2.75 billion04/15/2025$29.78$29.66-0.40%$30.46$29.23544,923 shs$2.76 billion04/14/2025$29.11$29.78+2.30%$30.34$28.60911,437 shs$2.77 billion04/11/2025$26.85$29.11+8.42%$29.26$26.411.38 million shs$2.71 billion04/10/2025$27.66$26.85-2.93%$27.17$25.381.17 million shs$2.50 billion04/09/2025$25.56$27.66+8.22%$27.85$24.101.59 million shs$2.57 billion04/09/2025$25.56$27.66+8.22%$27.85$24.101.59 million shs$2.57 billion04/08/2025$26.38$25.56-3.11%$27.27$25.111.47 million shs$2.38 billion04/08/2025$26.38$25.56-3.11%$27.27$25.111.47 million shs$2.38 billion04/07/2025$26.89$26.38-1.90%$27.23$24.711.63 million shs$2.45 billion04/04/2025$28.87$26.89-6.86%$28.54$26.481.21 million shs$2.50 billion04/03/2025$31.39$28.87-8.03%$30.10$28.481.15 million shs$2.69 billion04/02/2025$30.62$31.39+2.51%$31.68$30.061.16 million shs$2.92 billion04/01/2025$33.54$30.62-8.71%$33.42$29.182.20 million shs$2.85 billion03/31/2025$34.73$33.54-3.43%$34.54$31.652.43 million shs$3.12 billion Related Companies Ascendis Pharma A/S Stock Chart Moderna Stock Chart Viatris Stock Chart Qiagen Stock Chart Roivant Sciences Stock Chart Lantheus Stock Chart Revolution Medicines Stock Chart BridgeBio Pharma Stock Chart Legend Biotech Stock Chart TG Therapeutics Stock Chart Receive CRNX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:CRNX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
